Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nadheer Issa

Internal Medicine Sterling Heights, MI Medical Doctor

NPI 1568444677 CMS profile 25697

44344 Dequindre Rd, Suite 540, Sterling Heights, MI 48314

Open in the dashboard

General payments

$5,219

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nadheer Issa of Sterling Heights, MI is reported in the CMS Open Payments database as having received $5,219 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,779 85
2024 General $1,138 60
2023 General $811 41
2022 General $1,015 65
2021 General $389 25
2020 General $27 2
2019 General $59 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadheer Issa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nadheer Issa were reported at $1,779. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nadheer Issa Internal Medicine median Middle half National median
2019 $59 $159 $48–$570 $163
2020 $27 $119 $33–$402 $114
2021 $389 $135 $37–$521 $132
2022 $1,015 $141 $42–$496 $149
2023 $811 $149 $45–$519 $160
2024 $1,138 $154 $47–$537 $164
2025 $1,779 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $815 52 payments
  2. Amgen Inc. $782 50 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $654 33 payments
  4. AstraZeneca Pharmaceuticals LP $582 25 payments
  5. Pfizer Inc. $233 12 payments
  6. Ardelyx, Inc. $206 11 payments
  7. Sumitomo Pharma America, Inc. $157 7 payments
  8. Lilly USA, LLC $148 9 payments
  9. Alnylam Pharmaceuticals Inc. $139 1 payment
  10. Corcept Therapeutics $138 6 payments
  11. Other $1,365 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,122 280 payments
  2. Education $97 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $723 46 payments
  2. RYBELSUS $674 43 payments
  3. JARDIANCE $401 20 payments
  4. AIRSUPRA $364 13 payments
  5. FARXIGA $353 10 payments
  6. Repatha $291 18 payments
  7. EVENITY $221 13 payments
  8. Prolia $211 13 payments
  9. IBSRELA $206 11 payments
  10. ELIQUIS $193 10 payments
  11. Other $3,469 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 207 drugs

Part D claims

22,247

Median for Internal Medicine: 777

Drug cost

$3,140,771

Median for Internal Medicine: $73,373

Branded share of claims

26.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 508 $517,260
Ozempic Semaglutide Brand 244 $373,284
Eliquis Apixaban Brand 379 $366,865
Rybelsus Semaglutide Brand 107 $176,426
Linzess Linaclotide Brand 268 $156,430
Tradjenta Linagliptin Brand 215 $152,230
Farxiga Dapagliflozin Propanediol Brand 169 $149,203
Trulicity Dulaglutide Brand 85 $105,481
Prolia Denosumab Brand 61 $102,319
Xarelto Rivaroxaban Brand 96 $99,453

The 10 drugs with the highest cost, of 207 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$181,943

Of which drugs: $7,433

Medicare patients

379

Average age 77

Services billed

4,595

187 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 48%
Ischemic heart disease 44%
Chronic kidney disease 39%
Heart failure 22%
Atrial fibrillation 21%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 88 88 $7,200
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 38 116 $112
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 15 15 $0
Injection, denosumab, 1 mg J0897 Office 13 14 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $138
  • Lilly USA, LLC $7
$145 508 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $140
$140 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $119
$119 169 —
GEMTESA
  • Sumitomo Pharma America, Inc. $94
$94 46 —
Repatha
  • Amgen Inc. $91
$91 79 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record